/
GDTC
$1.00-$0.02 (-1.96%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$12.1M
12M shares
52-week range
$0.68 – $3.68
11% from low
Exchange
NASDAQ
CS
Borrow rate
4.31%
Moderate
Price (6 mo)
Loading chart…
Change$-3.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $365.6K | $509.1K | $69.5K | $319.2K |
| Cost of revenue | $0 | $4.6K | $3.5K | $109.0K | $3.7K | $17.1K | $1.2M |
| Gross profit | $0 | $54.8K | $110.3K | −$109.0K | $505.4K | $52.4K | −$886.6K |
| Gross margin | — | — | — | -29.8% | 99.3% | 75.4% | -277.7% |
| R&D | $439.8K | $1.0M | $1.1M | $1.5M | $1.6M | $2.0M | $2.2M |
| Operating income | −$651.9K | −$1.3M | −$1.2M | −$2.3M | −$1.6M | −$3.1M | −$4.5M |
| EBITDA | −$474.6K | −$1.0M | −$1.4M | −$1.5M | −$3.9M | −$2.4M | −$4.3M |
| Net income | −$858.7K | −$1.9M | −$2.1M | −$3.1M | −$4.1M | −$2.6M | −$3.9M |
| Net margin | — | — | — | -835.7% | -814.0% | -3699.7% | -1227.1% |
| EPS (diluted) | -0.15 | -0.33 | -0.30 | -0.40 | -0.38 | -0.22 | -0.33 |
Annual figures · source: Financial Modeling Prep
Peer comparison
CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
w2.cytomed.sg- Employees
- 42
- IPO / List date
- Apr 14, 2023
Held by traders on TradeandTell
No one on the platform currently holds GDTC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GDTC as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GDTC yet.
